Alcon acquires Optinol and enters glaucoma surgical market.
Alcon has entered into the surgical glaucoma market by acquiring Optonol, a manufacturer and marketer of novel minature surgical implants used to reduce IOP.
The move will enable Alcon to acquire the Ex-PRESS Mini Glaucoma Shunt to complement its pharmaceutical products that lower IOP. The acquisition of Optonol is part of our strategy to bolster organic growth with targeted investments in key therapeutic areas that have the potential to contribute in both the near and long term, said Kevin Buehler, Alcon's president and chief executive officer. Because the product is already approved in the United States and other major markets it will begin contributing commercially in 2010.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.